AMBEA Share Price | Ambea AB Stock Analysis & Recommendation

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Compare Ambea AB with Similar Stocks

AddLife AB Medicover AB Humana AB

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Operating profit has grown by an annual rate 15.79% of over the last 5 years

The company has declared Positive results for the last 6 consecutive quarters

With ROE of 13.24%, it has a fair valuation with a 2.11 Price to Book Value

Consistent Returns over the last 3 years

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 11,009 Million (Small Cap)

P/E

16.00

Industry P/E

Dividend Yield

119.32%

Debt Equity

0.88

Return on Equity

13.52%

Price to Book

2.05

Revenue and Profits:

Net Sales:

4,088 Million

(Quarterly Results - Jun 2025)

Net Profit:

95 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

12.55%

6 Months

18.56%

1 Year

40.11%

2 Years

178.41%

3 Years

253.1%

4 Years

177.03%

5 Years

96.49%

Ambea AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Ambea AB Reports Strong Financial Performance in Pharmaceuticals Sector

Ambea AB, a small-cap player in the Pharmaceuticals & Biotechnology sector, has demonstrated impressive financial results for the quarter ending March 2025. The company's performance highlights its ability to navigate the market effectively, showcasing significant growth across various financial metrics.

One of the standout figures from the latest financial report is the operating cash flow, which reached an all-time high of SEK 1,943 MM. This indicates a robust ability to generate cash from operations, a critical factor for sustaining business growth and funding future initiatives.

Additionally, the return on capital employed (ROCE) for the half-year period has also peaked at 12.75%, reflecting efficient use of capital in generating profits. This metric is particularly important for investors as it provides insight into how well the company is utilizing its resources to ...

Read full news article

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

6.84%

EBIT Growth (5y)

15.79%

EBIT to Interest (avg)

1.87

Debt to EBITDA (avg)

1.91

Net Debt to Equity (avg)

0.71

Sales to Capital Employed (avg)

1.62

Tax Ratio

23.90%

Dividend Payout Ratio

30.50%

Pledged Shares

Institutional Holding

ROCE (avg)

8.59%

ROE (avg)

9.03%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.11

EV to EBIT

12.78

EV to EBITDA

5.90

EV to Capital Employed

1.56

EV to Sales

1.03

PEG Ratio

0.71

Dividend Yield

124.26%

ROCE (Latest)

12.23%

ROE (Latest)

13.24%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 16.17% vs 6.31% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 106.52% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,088.00",
          "val2": "3,519.00",
          "chgp": "16.17%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "631.00",
          "val2": "547.00",
          "chgp": "15.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "133.00",
          "val2": "119.00",
          "chgp": "11.76%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-25.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "95.00",
          "val2": "95.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "62.40%",
          "val2": "58.30%",
          "chgp": "0.41%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 6.63% vs 5.36% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 36.26% vs 24.32% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "14,195.00",
          "val2": "13,312.00",
          "chgp": "6.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,480.00",
          "val2": "1,946.00",
          "chgp": "27.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "464.00",
          "val2": "419.00",
          "chgp": "10.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-9.00",
          "val2": "-14.00",
          "chgp": "35.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "620.00",
          "val2": "455.00",
          "chgp": "36.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "78.40%",
          "val2": "48.80%",
          "chgp": "2.96%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

4,088.00

3,519.00

16.17%

Operating Profit (PBDIT) excl Other Income

631.00

547.00

15.36%

Interest

133.00

119.00

11.76%

Exceptional Items

-25.00

0.00

Consolidate Net Profit

95.00

Operating Profit Margin (Excl OI)

62.40%

58.30%

0.41%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 16.17% vs 6.31% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.00% vs 106.52% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

14,195.00

13,312.00

6.63%

Operating Profit (PBDIT) excl Other Income

2,480.00

1,946.00

27.44%

Interest

464.00

419.00

10.74%

Exceptional Items

-9.00

-14.00

35.71%

Consolidate Net Profit

620.00

455.00

36.26%

Operating Profit Margin (Excl OI)

78.40%

48.80%

2.96%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 6.63% vs 5.36% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 36.26% vs 24.32% in Dec 2023

All Annual Results

Company CV

About Ambea AB

Ambea AB

Pharmaceuticals & Biotechnology

Ambea AB (publ) is a Sweden-based holding company within the care provider group. The Ambea group offers accommodation, support, training and staffing within health and social care. The Group has over 450 units throughout Sweden and in Norway. The Swedish operations comprise the brands Vardaga, Lara and Bemanning. Among other brands, there are Rent a Doctor, Rent a Nurse, Rent a Socionom and Careteam, as well as BoA Mellanvard. The Norwegian operations comprise support and residential care in disabilities and psychiatry through the companies Heimta and Vitale. The Company’s main shareholders are ACTR Holding Ab and Actor General Partner SARL Sweden SCA. It operates Malrettet Intervensjon AS, Elevhalsan, Stod och Resurs AB and Tiltaksgruppa fokus as subsidiaries.

Company Coordinates

Company Details

Evenemangsgatan 21, 6 tr, Box 1565 , SOLNA None : 171 29

Tel: 46 8 5787000046 495 40752

https://www.ambea.com/

Registrar Details